曲唑酮合并氟西汀对男性抑郁症患者性功能障碍的疗效

The effects of trazodone plus fluoxetine in the sexual dysfunction of male depression patients

目的观察曲唑酮合并氟西汀对男性抑郁症患者性功能障碍的疗效及安全性。方法将60例符合入组标准的男性抑郁症患者随机分为研究组（30例）和对照组（30例），研究组予以氟西汀合并曲唑酮治疗，对照组单用氟西汀治疗，疗程8周。于入组时及治疗后1，2，4，8周采用汉密尔顿抑郁量表17项（HAMD）、汉密尔顿焦虑量表（HAMA）、国际勃起功能指数问卷（IIEF-5）进行疗效评定。结果治疗第8周末2组HAMD、HAMA总分[（4．00±2．98）分，（3．30±2．64）分；（5．83．4-3．23）分，（4．53±3．64）分]与入组时比较，均差异有显著性（P〈0．01）。治疗第8周末研究组IIEF-5评分优于对照组（P〈0．01）。研究组痊愈8例，显效16例，有效4例，无效2例；对照组分别为2例，13例，6例，9例。2组疗效差异具有显著性（P〈0．05）。不良反应发生率研究组33．3％，对照组27．3％。结论曲唑酮合并氟西汀对男性抑郁症患者性功能障碍有较好的疗效，安全性较高。

Objective To explore the efficacy and safety of trazodone plus fluoxetine in the sexual dysfunction of male depression patients. Methods 60 depression patients were randomly divided into research group （ n = 30 ） and control group （ n = 30 ）. The patients of research group were treated with trazodone plus fluoxetine, patients of control group were treated with fluoxetine. The study lasted for 8 weeks. Before treatment and at the end of 1st, 2nd, 4th, 8th week after treatment, patients were evaluated with HAMD, HAMA, IIEF-5. Results The improvement of sex dysfunction： the remission rate, significant improvement rate, improvement rate and non-response rate of the research group was 26.67%, 53.33% , 13.33% , 6.67%. The control group was 6.67% ,43.33%, 20.00%, 30.00%. There was significant difference between two groups （ X^2 = 8. 765, P 〈 0.05 ）. The side effects rate was 33.3% in research group and 27.3% in control group. Conclusion Trazodone plus fluoxetine showed good efficacy and safety in treating sexual dysfunction disorder in male depression patients.